JP2022553652A5 - - Google Patents

Info

Publication number
JP2022553652A5
JP2022553652A5 JP2022521680A JP2022521680A JP2022553652A5 JP 2022553652 A5 JP2022553652 A5 JP 2022553652A5 JP 2022521680 A JP2022521680 A JP 2022521680A JP 2022521680 A JP2022521680 A JP 2022521680A JP 2022553652 A5 JP2022553652 A5 JP 2022553652A5
Authority
JP
Japan
Prior art keywords
product according
weight
highly lipophilic
cannabinoid
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022521680A
Other languages
English (en)
Japanese (ja)
Other versions
JP7850068B2 (ja
JP2022553652A (ja
Filing date
Publication date
Priority claimed from EP19203549.1A external-priority patent/EP3808336A1/de
Application filed filed Critical
Publication of JP2022553652A publication Critical patent/JP2022553652A/ja
Publication of JP2022553652A5 publication Critical patent/JP2022553652A5/ja
Priority to JP2025279962A priority Critical patent/JP2026034780A/ja
Application granted granted Critical
Publication of JP7850068B2 publication Critical patent/JP7850068B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022521680A 2019-10-16 2020-10-16 高親油性生理活性物質の放出制御製剤 Active JP7850068B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025279962A JP2026034780A (ja) 2019-10-16 2025-12-24 高親油性生理活性物質の放出制御製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19203549.1 2019-10-16
EP19203549.1A EP3808336A1 (de) 2019-10-16 2019-10-16 Kontrolliert freisetzende formulierungen stark lipophiler physiologisch aktiver substanzen
PCT/EP2020/079244 WO2021074399A1 (de) 2019-10-16 2020-10-16 Kontrolliert freisetzende formulierungen stark lipophiler physiologisch aktiver substanzen

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025279962A Division JP2026034780A (ja) 2019-10-16 2025-12-24 高親油性生理活性物質の放出制御製剤

Publications (3)

Publication Number Publication Date
JP2022553652A JP2022553652A (ja) 2022-12-26
JP2022553652A5 true JP2022553652A5 (https=) 2023-10-19
JP7850068B2 JP7850068B2 (ja) 2026-04-22

Family

ID=68281165

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022521680A Active JP7850068B2 (ja) 2019-10-16 2020-10-16 高親油性生理活性物質の放出制御製剤
JP2025279962A Pending JP2026034780A (ja) 2019-10-16 2025-12-24 高親油性生理活性物質の放出制御製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025279962A Pending JP2026034780A (ja) 2019-10-16 2025-12-24 高親油性生理活性物質の放出制御製剤

Country Status (10)

Country Link
US (1) US20240148758A1 (https=)
EP (2) EP3808336A1 (https=)
JP (2) JP7850068B2 (https=)
CN (1) CN114929197A (https=)
AU (1) AU2020366134B2 (https=)
BR (1) BR112022006678A2 (https=)
CA (1) CA3157693A1 (https=)
IL (1) IL292019A (https=)
MX (1) MX2022004522A (https=)
WO (1) WO2021074399A1 (https=)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4415547A (en) * 1982-06-14 1983-11-15 Sterling Drug Inc. Sustained-release pharmaceutical tablet and process for preparation thereof
DE69942928D1 (de) * 1998-08-27 2010-12-23 Pfizer Health Ab Therapeutische formulierung zur verabreichung von tolterodin mit kontrollierter freisetzung
DE10226494A1 (de) * 2002-06-14 2004-01-08 Lts Lohmann Therapie-Systeme Ag Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen
WO2008021394A2 (en) * 2006-08-15 2008-02-21 Theraquest Biosciences, Llc Pharmaceutical formulations of cannabinoids and method of use
WO2008024490A2 (en) 2006-08-24 2008-02-28 Theraquest Biosciences, Inc. Oral pharmaceutical formulations of abuse deterrent cannabinoids and method of use
WO2012048045A1 (en) * 2010-10-05 2012-04-12 Jb Therapeutics, Inc. Compositions, dosages, and methods of using tetrahydrocannabinol derivatives
CA2929321C (en) 2013-10-29 2022-04-05 Echo Pharmaceuticals B.V. Compressed tablet containing cannabidiol, method for its manufacture and use of such tablet in oral treatment of psychosis or anxiety disorders
WO2018035030A1 (en) 2016-08-15 2018-02-22 Corr-Jensen Inc. Time release fat-soluble actives
EP3808341A1 (de) * 2019-10-16 2021-04-21 ADD Advanced Drug Delivery Technologies, Ltd. Kontrolliert freisetzende formulierungen stark lipophiler physiologisch aktiver substanzen

Similar Documents

Publication Publication Date Title
CA2102777C (fr) Nouvelles compositions a base de derives de la classe des taxanes
EP3490575B2 (fr) Extrait de plante tres concentre en safranal, procede d'obtention et utilisations
CA2310147C (fr) Spheroides, procede de preparation et compositions pharmaceutiques
JP2022553653A5 (https=)
JP5160409B2 (ja) 外用の医薬組成物
FR2761266A1 (fr) Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates
CH678273A5 (https=)
JP2025182116A (ja) 高親油性生理活性物質の放出制御製剤
JP2025182116A5 (https=)
JP2022553652A5 (https=)
WO2020193997A1 (en) Carrier system for preparing herbaceous extracts
JP6308137B2 (ja) 皮膚適用製剤
LU83806A1 (fr) Utilisation d'hydroxynaphtoquinones pour la teinture des fibres keratiniques humaines,procede de teinture les mettant en oeuvre et composition tinctoriale utilisee
EA015440B1 (ru) Твердая лекарственная форма, содержащая полиморфную форму 1 клопидогрела гидросульфата
JP7850068B2 (ja) 高親油性生理活性物質の放出制御製剤
JP2024514171A (ja) カンナビノイドの製剤
CN117460709A (zh) 可用作染发剂的化合物
JP2017506647A (ja) 爪真菌症を治療するための局所用抗真菌薬組成物
EP4074307B1 (en) Formulations of cannabinoids
CN101222929A (zh) 银杏提取物
JP2002047191A (ja) ギンコビロバ抽出物の水溶性複合体、及びギンコビロバ抽出物の水溶性複合体調製方法
CA2184699A1 (fr) Composition immunomodulatrice utile en particulier pour le traitement des infections provoquees par vih
JP2002047146A (ja) 発毛剤
FR3031678A1 (fr) Utilisation conjointe de asp-8adt et d'un inhibiteur d'autophagie dans le traitement de cancer.
JP2011042641A (ja) 皮膚発赤改善剤